We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · January 27, 2021

Pembrolizumab, Dabrafenib, and Trametinib Improves Outcomes in BRAF-Mutant Melanoma

Journal for immunotherapy of cancer

 

Additional Info

Journal for immunotherapy of cancer
KEYNOTE-022 Part 3: A Randomized, Double-Blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-Mutant Melanoma
J Immunother Cancer 2020 Dec 01;8(2)e001806, PF Ferrucci, AM Di Giacomo, M Del Vecchio, V Atkinson, H Schmidt, J Schachter, P Queirolo, GV Long, R Stephens, IM Svane, M Lotem, M Abu-Amna, E Gasal, R Ghori, SJ Diede, ES Croydon, A Ribas, PA Ascierto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading